Key Drivers
- Quarterly Turnaround
- Strong Liquidity
- High Valuation
AIAI Summary
ATRC's investment case has shifted to a profitability-inflection story, with 77% gross margins, positive earnings, and strong free cash flow supporting durable operating leverage—but at ~180x earnings and 46.8x EV/EBITDA, investors should await repeated margin execution and clinical-adoption progress before chasing a stock already above consensus targets.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Quarterly Turnaround
- •Strong Liquidity
- •High Valuation
ATRC's improving quarterly profitability, strong cash generation, and low leverage are offset by uneven annual returns and a demanding valuation.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Resistance test
- •Pullback risk
ATRC gained ~22% over the last month and remains bullish above $56.22–$57.14, but investors should watch for confirmation above $59.12 amid elevated pullback risk.
Accelerated advance after breaking above $48–$49
Sentiment & News
Key News Insights:
- •52-Week High
- •Product Platform
- •Competitive Pressure
AtriCure's stock momentum and product breadth support a constructive outlook, though competitive ablation pressures and modest insider selling warrant monitoring.
Recent strength may sustain investor interest, but growth and margin risks from pulsed-field ablation competition remain a key watchpoint
Similar Companies in Healthcare
Other companies in the same sector with AI ratings